Feature Story: |
Medtronic Launches First 2.0 mm Drug-Eluting Stent in United States |
Designed specifically for small vessels, Medtronic announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx(TM) 2.0 mm Drug-Eluting Stent (DES) – the smallest sized DES on the market. The new stent is intended to help interventional cardiologists treat patients with coronary artery disease (CAD) who have small vessels often untreatable with larger stent technologies during percutaneous coronary intervention (PCI). It is estimated that approximately 65 percent of smaller vessels (<= 2.25 mm) are in critical locations of the heart, making them significant lesions to treat.
“Patients with lesions in small vessels or complex vasculatures can present unique...
Read more online
|
|
Access Vascular, a medical device company reinventing venous access using proprietary material technology designed to reduce thrombus accumulation, announced that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its lead product, the HydroPICC™, a peripherally inserted central catheter, intended for long-term use. In pre-clinical testing, the HydroPICC demonstrated a 30x reduction in platelet count when compared with current market-leading PICC.
“The FDA clearance of the HydroPICC catheter is an important milestone for Access Vascular and a critical step forward on... read more} |
|
|
Contego Medical, LLC has announced the beginning of enrollment in the PERFORMANCE I Trial, a clinical trial designed to evaluate the safety and feasibility of the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection. The Neuroguard IEP System is designed to treat clinically significant carotid artery stenosis, further expanding Contego Medical’s portfolio of neurovascular solutions.
Prof. Saško Kedev, M.D., Ph.D., of University Clinic of Cardiology in Skopje, Macedonia treated the first patient enrolled in the PERFORMANCE I Trial. “We are pleased to initiate this trial evaluating the Neuroguard IEP System, the first of its kind for carotid stenting,” remarked Prof. Kedev. “Protection from... read more} |
|
South Texas Blood & Tissue Center, a subsidiary of BioBridge Global, today launched a program to aid accident and trauma patients served by area air medical services and hospital helicopters. The program, “Brothers in Arms,” will enable air medical crews to administer special pre-hospital transfusions of whole blood, proven to counter blood loss and dramatically improve survival rates when tested in battlefield situations.
San Antonio is one of the first cities to implement the system, which is based on a battlefield transfusion program developed by the U.S. military and later adapted at the Mayo Clinic trauma center. The 75th Ranger Regiment “O Low-Titer Whole Blood Program” was the recipient of ... read more} |
|
|
|
|